These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 16721567)
1. Is 3'-deoxy-3'-(18)F-fluorothymidine a better marker for tumour response than (18)F-fluorodeoxyglucose? Reske SN; Deisenhofer S Eur J Nucl Med Mol Imaging; 2006 Jul; 33 Suppl 1():38-43. PubMed ID: 16721567 [TBL] [Abstract][Full Text] [Related]
2. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975 [TBL] [Abstract][Full Text] [Related]
3. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts]. Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377 [TBL] [Abstract][Full Text] [Related]
5. 3'-deoxy-3'-(18)F-fluorothymidine (FLT) positron emission tomography for early prediction of response to chemoradiotherapy--a clinical application model of esophageal cancer. Chao KS Semin Oncol; 2007 Apr; 34(2 Suppl 1):S31-6. PubMed ID: 17449350 [TBL] [Abstract][Full Text] [Related]
6. Molecular PET and PET/CT imaging of tumour cell proliferation using F-18 fluoro-L-thymidine: a comprehensive evaluation. Barwick T; Bencherif B; Mountz JM; Avril N Nucl Med Commun; 2009 Dec; 30(12):908-17. PubMed ID: 19794320 [TBL] [Abstract][Full Text] [Related]
7. (18)F-FDG and (18)F-FLT uptake early after cyclophosphamide and mTOR inhibition in an experimental lymphoma model. Brepoels L; Stroobants S; Verhoef G; De Groot T; Mortelmans L; De Wolf-Peeters C J Nucl Med; 2009 Jul; 50(7):1102-9. PubMed ID: 19525456 [TBL] [Abstract][Full Text] [Related]
8. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer? Schaefferkoetter JD; Carlson ER; Heidel RE J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746 [TBL] [Abstract][Full Text] [Related]
9. Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Ullrich R; Backes H; Li H; Kracht L; Miletic H; Kesper K; Neumaier B; Heiss WD; Wienhard K; Jacobs AH Clin Cancer Res; 2008 Apr; 14(7):2049-55. PubMed ID: 18381944 [TBL] [Abstract][Full Text] [Related]
11. Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results. Bhoil A; Singh B; Singh N; Kashyap R; Watts A; Sarika S; Mittal BR Hell J Nucl Med; 2014; 17(2):90-6. PubMed ID: 24997081 [TBL] [Abstract][Full Text] [Related]
12. Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls. Herrmann K; Buck AK PET Clin; 2014 Jul; 9(3):331-8. PubMed ID: 25030396 [TBL] [Abstract][Full Text] [Related]
13. Predictive Value of Early-Stage Uptake of 3'-Deoxy-3'-18F-Fluorothymidine in Cancer Cells Treated with Charged Particle Irradiation. Lin C; Kume K; Mori T; Martinez ME; Okazawa H; Kiyono Y J Nucl Med; 2015 Jun; 56(6):945-50. PubMed ID: 25766892 [TBL] [Abstract][Full Text] [Related]
14. FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy. Katz SI; Zhou L; Ferrara TA; Wang W; Mayes PA; Smith CD; El-Deiry WS Int J Oncol; 2011 Jul; 39(1):91-100. PubMed ID: 21537838 [TBL] [Abstract][Full Text] [Related]
15. [(18)F]FLT-PET imaging does not always "light up" proliferating tumor cells. Zhang CC; Yan Z; Li W; Kuszpit K; Painter CL; Zhang Q; Lappin PB; Nichols T; Lira ME; Affolter T; Fahey NR; Cullinane C; Spilker M; Zasadny K; O'Brien P; Buckman D; Wong A; Christensen JG Clin Cancer Res; 2012 Mar; 18(5):1303-12. PubMed ID: 22170262 [TBL] [Abstract][Full Text] [Related]
16. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. van Waarde A; Cobben DC; Suurmeijer AJ; Maas B; Vaalburg W; de Vries EF; Jager PL; Hoekstra HJ; Elsinga PH J Nucl Med; 2004 Apr; 45(4):695-700. PubMed ID: 15073267 [TBL] [Abstract][Full Text] [Related]
17. Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models. Cullinane C; Dorow DS; Jackson S; Solomon B; Bogatyreva E; Binns D; Young R; Arango ME; Christensen JG; McArthur GA; Hicks RJ J Nucl Med; 2011 Aug; 52(8):1261-7. PubMed ID: 21764800 [TBL] [Abstract][Full Text] [Related]
18. Early detection of chemoradioresponse in esophageal carcinoma by 3'-deoxy-3'-3H-fluorothymidine using preclinical tumor models. Apisarnthanarax S; Alauddin MM; Mourtada F; Ariga H; Raju U; Mawlawi O; Han D; Bornmann WG; Ajani JA; Milas L; Gelovani JG; Chao KS Clin Cancer Res; 2006 Aug; 12(15):4590-7. PubMed ID: 16899606 [TBL] [Abstract][Full Text] [Related]
19. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare. Lee SJ; Kim SY; Chung JH; Oh SJ; Ryu JS; Hong YS; Kim TW; Moon DH Biochem Pharmacol; 2010 Nov; 80(10):1528-36. PubMed ID: 20723540 [TBL] [Abstract][Full Text] [Related]
20. Kinetic modeling of 3'-deoxy-3'-18F-fluorothymidine for quantitative cell proliferation imaging in subcutaneous tumor models in mice. Kim SJ; Lee JS; Im KC; Kim SY; Park SA; Lee SJ; Oh SJ; Lee DS; Moon DH J Nucl Med; 2008 Dec; 49(12):2057-66. PubMed ID: 18997037 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]